Fierce Biotech · 23 Oct, 03:36 · Business briefing

Treasury sweeps biotech into proposed COINS Act restrictions, but spares Big Pharma’s China licensing deals

The US Treasury has included biotechnology firms within the proposed COINS Act restrictions, targeting specific supply chain and investment activities.

What it means for you ↓ Courses for this story

26%average salary uplift after a professional certificate

2.7xfaster promotion for certified professionals

71%of leaders prefer candidates who upskill continuously

20days to your first credential

The briefing

The story
in brief.

What happened, who it affects, and why it landed on our intelligence desk — in plain English, sixty seconds or less.

The US Treasury has included biotechnology firms within the proposed COINS Act restrictions, targeting specific supply chain and investment activities. However, major pharmaceutical companies are explicitly exempted from these rules regarding their licensing agreements with Chinese entities. This regulatory distinction creates a fragmented compliance landscape, forcing smaller biotech organisations to navigate stringent new constraints while established giants maintain existing commercial frameworks. Professionals must monitor these evolving policy details to understand how differing regulatory burdens will reshape operational strategies and cross-border partnerships across the healthcare sector.

Employer demand for Compliance And Governance skills — indexed growth since 2019
Indicative index of skill mentions in professional job postings for the field this story moves (2019 = 1)

Your move

What this means
for your career.

Every headline redistributes opportunity. Here is who this one rewards — and how to be on the right side of it.

You must prioritise regulatory compliance and geopolitical risk assessment skills immediately. This divergence means biotech professionals need to master complex international trade laws, whereas pharma roles may focus on maintaining legacy licensing structures. If you work in biotech, deepen your expertise in compliance and governance to navigate these new Treasury restrictions. For those in Big Pharma, focus on strategic contract management to protect current China deals. A smart professional would now audit their current cross-border collaborations for vulnerability. Upskill in risk management and international business law to advise leadership on mitigating regulatory exposure. This shift rewards those who can translate policy nuance into actionable corporate strategy, making compliance officers and strategic advisors highly valuable in the coming months.

For this story, the fields that convert it into pay are Compliance And Governance, Risk Management Strategies, Healthcare Management and Law — exactly the programmes matched below. The chart shows the indicative salary uplift certified professionals report in each of those fields; every one of them is a click away, from £79, finishing in as few as 20 days.

Indicative salary uplift in the fields matched to this story
Indicative ranges from published continuing-education salary studies, by field — each field is a recommended course below

Matched to this story

Enrol in these
to benefit.

These programmes position you for exactly this shift — online, self-paced, and finishing with a verifiable certificate you can share the day you pass.